The Palisades Nuclear Plant Demands a Clear Risk-Based Analysis for Successful Reopening

 

The debate around restarting mothballed nuclear power plants is gaining momentum in the U.S., illustrated by the decision to revive the long-dormant Palisades Nuclear Plant. This pioneering move, marking the first such initiative in the nation, underscores a broader conversation about energy resilience and the strategic recalibration of America’s energy assets. Experts say to ensure quality restarts of power generation at the plant, a clear risk-based analysis is key for success.

The Palisades Nuclear Plant in Michigan is en route to reopening its doors after receiving a $1.52 billion federal loan. A few key things are still up in the air before the plant can start to contribute to the nation’s 100% renewable energy by 2035 goal. Mainly, the Palisades Nuclear Plant’s operator, Holtec, needs to get restoration approval from the nuclear regulatory commission, approving the relaunch of a station that ran for 45 years.

The task is fraught with complexities, from navigating stringent regulatory landscapes to managing the logistics of an aging supply chain that hasn’t supported new builds in over three decades, all shaped but the pragmatic safety considerations of relaunching a nuclear power plant that’s laid dormant for several years.

Is reopening the Palisades Nuclear Plant a risk, or is it primed for a successful restart? The Honorable Bud Albright, who brings over 30 years of experience in both the U.S. Department of Justice and the energy sector, gives his perspective on the feasibility, risks, and strategic implications of such a restart, and helps give some guidance on paths forward in this critical discourse.

“There are risks that are clearly unknown simply because it’s the first of a kind. I anticipate that those are relatively limited, limited risks. I think the things that I would be most concerned with, major issues, would be the NRC review,” Albright said. “What’s the standard going to be? Will they be using scientifically sound risk-based analysis as they do their analysis?”

Article written by Daniel Litwin.

Follow us on social media for the latest updates in B2B!

Image

Latest

career
Stop Chasing Titles, Build a Career That Matters – From a CAO
March 11, 2026

Career advice in finance and accounting often centers around promotions, titles, and compensation. But in an era where professionals frequently change jobs every few years—the average American worker now stays in a role less than four years—industries are facing growing talent shortages and reevaluating what long-term career success looks like. The question many professionals are…

Read More
Career success
A CEO’s Blueprint for Career Success: Leading with Love to Drive Performance and Culture
March 10, 2026

Leadership right now feels heavier than it did just a few years ago. Teams are stretched, expectations are high, and many employees are quietly disengaged. In fact, Gallup’s 2025 U.S. data shows that only about 31% of employees are actively engaged at work, leaving the majority feeling disconnected or indifferent. For CEOs and senior…

Read More
employer-sponsored apprenticeships
The Degree That Pays You Back: How Employer-Sponsored Apprenticeships Are Rewriting Higher Ed
March 9, 2026

Higher education is under pressure. Over the past few years, public confidence in the value of a four-year degree has declined significantly, with fewer Americans expressing a strong belief that traditional higher education delivers a worthwhile return on investment. At the same time, employers consistently report that graduates lack job-ready skills—particularly the “durable skills”…

Read More
Denial Data
Turning Denial Data Into Action: How Healthcare Organizations Can Fight Back Against Payer Denials
March 5, 2026

Healthcare providers across the U.S. are facing a growing wave of claim denials that is putting pressure on already strained hospital finances. Industry research from the American Hospital Association shows that nearly 15% of medical claims submitted to private payers are initially denied, forcing hospitals and health systems to spend about $19.7 billion annually attempting…

Read More